IFRG15 Inhibitors
Chemical inhibitors of IFRG15 function by modulating the activity of cyclooxygenases (COX-1 and COX-2), enzymes that are critical in the production of prostaglandins, which are known to play a role in inflammation and immune responses. Acetylsalicylic Acid, ibuprofen, indomethacin, naproxen, and piroxicam are nonselective COX inhibitors, reducing the synthesis of prostaglandins by inhibiting the activity of both COX-1 and COX-2 enzymes. This reduction in prostaglandin synthesis can lead to a decrease in the functional activity of IFRG15, which is involved in modulating immune responses. Dexamethasone, a glucocorticoid, acts upstream by inhibiting phospholipase A2, an enzyme involved in the release of arachidonic acid, a precursor for prostaglandin synthesis, thereby reducing the production of prostaglandins and potentially the activity of IFRG15.
On the other hand, celecoxib, rofecoxib, valdecoxib, etoricoxib, and meloxicam are selective COX-2 inhibitors. By specifically targeting COX-2, they reduce the production of prostaglandins related to inflammatory responses without significantly affecting COX-1, which is more involved in maintaining physiological functions such as the protection of the gastric lining. Sulindac, a prodrug, upon metabolism, also inhibits COX enzymes, contributing to the reduction in prostaglandin synthesis. The selective inhibition of COX-2 by these chemicals can lead to a decrease in the activity of IFRG15 within the immune response pathways. The overall effect of these chemical inhibitors on IFRG15 is a functional inhibition, resulting from the diminished prostaglandin synthesis, which plays a role in the regulation of immune responses in which IFRG15 is implicated.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Aspirin | 50-78-2 | sc-202471 sc-202471A | 5 g 50 g | $20.00 $41.00 | 4 | |
Inhibits cyclooxygenases (COX-1 and COX-2), which may lead to a reduction in prostaglandins that are known to regulate inflammation. Given that IFRG15 is involved in immune responses, reducing prostaglandin synthesis could decrease the functional activity of IFRG15. | ||||||
Ibuprofen | 15687-27-1 | sc-200534 sc-200534A | 1 g 5 g | $52.00 $86.00 | 6 | |
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits COX-1 and COX-2, similar to acetylsalicylic acid. It could decrease prostaglandin levels, and thus possibly inhibit the immune-modulatory functions of IFRG15. | ||||||
Indomethacin | 53-86-1 | sc-200503 sc-200503A | 1 g 5 g | $28.00 $37.00 | 18 | |
As another NSAID, indomethacin inhibits COX enzymes more potently than ibuprofen or acetylsalicylic acid, potentially causing a more pronounced decrease in prostaglandin synthesis, which might reduce the immune response activities where IFRG15 is involved. | ||||||
Naproxen | 22204-53-1 | sc-200506 sc-200506A | 1 g 5 g | $24.00 $40.00 | ||
Naproxen, a COX inhibitor, may reduce prostaglandin synthesis and consequently dampen inflammatory responses. This could lead to a functional inhibition of IFRG15's role in such immune pathways. | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $76.00 $82.00 $367.00 | 36 | |
A glucocorticoid that acts as an anti-inflammatory by inhibiting phospholipase A2 and subsequently prostaglandin and leukotriene synthesis. This can lead to a decrease in inflammation, potentially inhibiting IFRG15's involvement in immune responses. | ||||||
Vioxx | 162011-90-7 | sc-208486 | 100 mg | $190.00 | 3 | |
Similar to celecoxib, rofecoxib is a selective COX-2 inhibitor, which could potentially inhibit the inflammatory pathways that IFRG15 is part of, leading to a functional inhibition of IFRG15. | ||||||
Piroxicam | 36322-90-4 | sc-200576 sc-200576A | 1 g 5 g | $107.00 $369.00 | 2 | |
As a non-selective COX inhibitor, piroxicam may decrease prostaglandin levels, which could lead to a functional inhibition of the immune response processes involving IFRG15. | ||||||
Meloxicam | 71125-38-7 | sc-200626 sc-200626A sc-200626B | 20 mg 100 mg 500 mg | $35.00 $92.00 $153.00 | 3 | |
Meloxicam preferentially inhibits COX-2 over COX-1 and may reduce prostaglandin synthesis, potentially inhibiting IFRG15's activity in immune response pathways. | ||||||
Etoricoxib | 202409-33-4 | sc-218446 | 10 mg | $35.00 | 3 | |
By selectively inhibiting COX-2, etoricoxib can potentially reduce prostaglandin synthesis and thus inhibit inflammatory pathways that IFRG15 is known to be part of, leading to functional inhibition of IFRG15. | ||||||
Sulindac | 38194-50-2 | sc-202823 sc-202823A sc-202823B | 1 g 5 g 10 g | $31.00 $84.00 $147.00 | 3 | |
Sulindac is a prodrug that, once metabolized, inhibits COX, potentially decreasing prostaglandin synthesis and inhibiting the inflammatory response pathways that IFRG15 is involved in, leading to its functional inhibition. | ||||||